Vaccine-derived Yellow Fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with Sofosbuvir
Yellow fever (YF) is a potentially lethal viral hemorrhagic fever transmitted to humans by Haemagogous and Aedes spp., (mainly Aedes aegypti). The risk of a YF infection for unvaccinated people during a two week stay in West Africa is about 50:100.000 and 5:100.000 in South America. Case fatality rates reach up to 40-60% in South America but are estimated at 20% in Africa [1] . The 17D live attenuated YF vaccine, which was developed in 1937 by Max Theiler, proved to be a highly effective method in preventing an outbreak of the symptomatic disease, but can also cause severe adverse reactions like YF vaccine-associated neurotropic disease (YEL-AND) or YF vaccine-associa ted viscerotropic disease (YEL-AVD) [2].
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tobias Weirauch, Gerrit Burger, D ániel Cadar, Martin Gabriel, Julia Koepsell, Gundolf Schüttfort, Philipp de Leuw, Markus Bickel, Maria J.G.T. Vehreschild, Timo Wolf, Nils Wetzstein Tags: Case Report Source Type: research
More News: African Health | Brain | Infectious Diseases | Neurology | Outbreaks | Vaccines | Yellow Fever | Yellow Fever Vaccination